Severity and 1-month outcome of SARS-CoV-2 infection in patients with solid cancers: a Danish nationwide cohort study

CONCLUSIONS: Acknowledging the low sample size in this study, our work shows that age and comorbidities, but not recent cytotoxic therapy, are associated with adverse outcomes of SARS-CoV-2 infection for patients with solid cancer. Particularly, patients with progressive disease seem to be at greater risk of a fatal outcome from COVID-19.HighlightsAge, performance status, and comorbidities are strong predictors of adverse outcome in cancer patients with SARS-CoV-2 infection.Patients with progressive cancer disease seem to be at greater risk of a fatal outcome from COVID-19.Recent cytotoxic therapy, however, did not seem to be associated with increased risk for adverse outcomes of SARS-CoV-2 infection for patients with solid cancer.PMID:33646071 | DOI:10.1080/0284186X.2021.1889659

Source: Acta Oncologica - March 1, 2021 Category: Cancer & Oncology Authors: S Ehmsen L H Jakobsen M E Lendorf R L Eefsen L Bentsen A S Knoop N Aggerholm-Pedersen H Skuladottir J Herrstedt L H Jensen C Rotb øl M B Damm K Wedervang A Glenth øj J Ryg H Frederiksen A R Kodahl Source Type: research